Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mupadolimab in hospitalized COVID-19
NCT04734873Phase 3Terminated
- Sponsor
- Corvus Pharmaceuticals
- Start
- Feb 2021
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of mupadolimab in coronavirus disease 2019 (COVID-19), sponsored by Corvus Pharmaceuticals. Started Feb 2021; status: terminated.
02
Drugs
mupadolimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04734873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04734873.